Opinion|Videos|October 28, 2024
Genetic Testing in Metastatic Prostate Cancer: Key Insights on Germline and Somatic Mutations
Author(s)Pedro Barata, MD, MSc, FACP
Key Takeaways
- Talazoparib in the TALAPRO-1 trial improved progression-free survival and overall response rates in metastatic prostate cancer with specific genetic alterations.
- Rucaparib in the TRITON3 trial showed superior progression-free survival compared to standard treatments, highlighting its efficacy in targeted patient populations.
Panelists discuss how PARP inhibitor monotherapy trials like TALAPRO-1 (talazoparib) and TRITON-3 (rucaparib) have demonstrated efficacy and safety in treating metastatic prostate cancer patients with homologous recombination repair gene alterations, providing important insights into targeted therapy options for this specific patient population.
Advertisement
Episodes in this series
Video Content above is prompted by the following:
- Discuss efficacy and safety findings from monotherapy trials of PARP inhibitors in metastatic prostate cancer harboring homologous recombination repair (gene alterations.
- TALAPRO-1 trial (talazoparib), NCT03148795
- TRITON3 trial (rucaparib), NCT02975934.
Advertisement
Related to this article
The designation was supported by findings from the phase 2 Co-PSMA trial, the phase 1/2 COBRA trial, and real-world evidence.
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.
Pasritamig is being evaluated with or without JNJ-9401 in the ongoing phase 3 KLK2-comPAS trial.
These FAQs outline key recommendations from ASTRO's updated guideline on shorter-course radiation therapy for localized prostate cancer.
Updated CAPItello-281 data support capivasertib plus abiraterone in PTEN-deficient mHSPC, according to Daniel J. George, MD.
Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.
Biomarkers including HRR mutations, PTEN loss, and PSMA expression can guide triplet selection in mHSPC, according to Benjamin Garmezy, MD.
Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.
Advertisement
Advertisement
Trending on Urology Times
1
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
2
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
3
BCG-naïve NMIBC: Optimizing initial treatment selection
4
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
5